Peprotech Cell Growth Cytokines
Added: Jun 27, 2018 4:11 pm SOURCES SOUGHT NOTICE1. Solicitation Number: NIHDA2018002892. Title: Brand Name Only Peprotech Cell Growth Cytokines3. Classification Code: 664. NAICS Code: 3254145. Description: This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement.This notice is issued to help determine the availability of qualified companies technically capable of supplying the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only.Background: To acquire cytokines from the same manufacturer of the lots previously used by our group in experiments. These will be used to culture hematopoietic stem cells and study the mechanisms of aging in these cells in an in-vitro contextPurchase Description: (1) Human and murine cytokines; (2) Human EPO, Human Flt3-Ligand, Murine Flt3-Ligand, Human IL-6, Murine IL-7, Murine IL-12 p70, Murine M-CSF, Human SCF, Murine SCF, Human TPO, Murine TPO, Murine Hematopoietic Stem Cell Expansion Pack Includes Murine IL-3, Human Hematopoietic Stem Cell Expansion Pack Includes Human IL-6; (3) Peprotech; (4) 100-64-500UG, 300-19-1MG, 250-31L-500UG, 200-06-500UG, 217-17-250UG, 217-17-100UG, 210-12-100UG, 210-12-500UG, 315-02-250UG, 300-07-1MG, 250-03-1MG, 300-18-500UG, 315-14-1MG, MHSC3, HHSC6Project requirements: Initial projects in the NIA would be a continuation of postdoctoral research aims which have been carried out for over 7 years. Keeping the reagents like cytokines especially for key cell culture experiments is of utmost importance to maintain the consistency and reproducibility of the ongoing part of the projects.Anticipated period of performance: No Later than 4 weeks after receipt of order.Capability statement /information sought. Respondents must provide evidence that they are an authorized distributor of the products listed.The respondent must also provide their DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HubZone, etc., pursuant to the applicable NAICS code and any other information that may be helpful in developing or finalizing the acquisition requirements.One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2" x 11" paper size, with 1" top, bottom, left and right margins, and with single or double spacing.The information submitted must be must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required.The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested.The response must include the respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses.All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted.The response must be submitted to Jon Gottschalk, at e-mail address jon.gottschalk@gmail.comThe response must be received on or before July 5, 2018, 3:00 pm, Eastern Time."Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work.Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation.Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)." NIHDA201800289 Department of Health and Human Services National Institutes of Health
6/27/18, 4:11 PM Peprotech Cell Growth Cytokines
NON-COMPETITIVE COMBINED SYNOPSIS / SOLICITATION Solicitation Number: NIHDA201800289 Title: Peprotech Cell Growth Cytokines (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. (ii) The solicitation number is NIHDA201800289 and the solicitation is issued as a Request for Quote. This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures; FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items; and FAR Part 12-Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition teshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition, Contracts Management Branch Blue on behalf of the National Institute on Aging intends to negotiate and award a Purchase Order without providing for full and open competition (Including brand-name) to Peprotech, Inc., 5 Crescent Ave, Rocky Hill, NJ 08553-0275 for Cell Growth Cytokines. This acquisition is conducted as non-competitive for a commercial item or service and is conducted under the authority of the FAR Subpart 13.5-Simplified Procedures for Certain Commercial Items and 13.501 Special documentation requirements and the authority of 41 U.S.C. 1901 and the statutory authority of 13.106-1(b)(1) - Brand Name Item. Pursuant to FAR Subpart 13.501 (a) (1) (iii) the justification (excluding brand name) will be made available within 14 days after contract award or in the case of unusual and compelling urgency within 30 days after contract award. Pursuant to FAR Subpart 13.501 (a) (1) (iv) the rationale for the brand name justification is that these reagents have been used since the commencement of a scientific project that require the continuous use of the same lots to maintain consistency. (iii) The solicitation document and incorporated provisions and clauses are those in effect tough Federal Acquisition Circular 2005-98, dated May 31, 2018. (iv) The associated NAICS code 325414 and the small business size standard 1,250 employees. This requirement is full and open with no set-aside restrictions. (v) List of contract line item number(s), name of items, quantities, units of measure and option quantities See Attached Product Description. (vi) Generic Name of Product: Cell Growth Cytokines (vii) Delivery: 30-45 Days ARO Place of Delivery: 251 Bayview Blvd Baltimore, MD 21224-2816 (viii) The provision at FAR clause 52.212-1, Instructions to Offerors - Commercial Items, applies to this acquisition. (ix) The provision at FAR clause 52.212-2, Evaluation - Commercial Items, applies to this acquisition. (a) The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Lowest-Price, Technically Acceptable. (b) A written notice of award or acceptance of an offer, mailed or otherwise furnished to the successful offeror within the time for acceptance specified in the offer, shall result in a binding contract without further action by either party. Before the offer's specified expiration time, the Government may accept an offer (or part of an offer), whether or not there are negotiations after its receipt, unless a written notice of withdrawal is received before award. (x) The Offerors to include a completed copy of the provision at FAR clause 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer. (xi) The FAR clause at 52.212-4, Contract Terms and Conditions - Commercial Items, applies to this acquisition. (xii) FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. (xiii) The following additional contract requirement(s) or terms and conditions as determined by the contracting officer are necessary for this acquisition and consistent with customary commercial practices: There are no additional contract requirement(s) or terms and conditions applicable to this acquisition. (xiv) The Defense Priorities and Allocations System (DPAS) are not applicable to this requirement. (xv) Responses to this solicitation must include sufficient information to establish the interested parties' bona-fide capabilities of providing the product or service. The price quote shall include: unit price, list price, shipping and handling costs, delivery days after contract award, delivery terms, prompt payment discount terms, F.O.B. Point (Destination or Origin), product or catalog number(s); product description; and any other information or factors that may be considered in the award decision. Such factors may include: past performance; special features required for effective program performance; trade-in considerations; probable life of the item selected as compared with that of a comparable item; warranty considerations; maintenance availability; and environmental and energy efficiency considerations. Respondents that believe that they are manufacturers or authorized resellers of the brand-name product specified in this announcement must provide, as part of their response: (a) product, catalog, model, and/or part number(s); (b) product description; (c) all relevant information and documentation that the item(s) offered meets the salient physical, functional, or performance characteristics as specified in the purchase description; quantity; estimated price or cost; shipping, handling, and/or installation charges; and delivery date after receipt of order. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received by 04:00 PM Eastern on July 24, 2018 and reference number NIHDA201800289. Responses may be submitted electronically to Jon Gottschalk, jon.gottschalk@nih.gov. Fax responses will not be accepted. (xvi) The name and telephone number of the individual to contact for information regarding the solicitation: Jon Gottschalk, 301-443-9456. NIHDA201800289 Department of Health and Human Services National Institutes of Health
7/17/18, 3:41 PM